6 results for "Head "
AG013-ODOM-201: Oral Mucositis in Head & Neck Cancer Patients and the Effects of Topically-applied AG013
The purpose of the study is to evaluate, safety and tolerability administered AG013 compared to placebo for reducing Oral Mucositis in patients undergoing chemoradiation for the treatment of head and neck cancer, as measured by the duration, time and development, and overall incidence of Om during the active treatment phase, beginning from the start of radiation therapy until 2 weeks following its completion.
RTOG-1008: RT +/- Chemotherapy for High-Risk Malignant Salivary Gland Tumors that have been Surgically Removed
This randomized phase II/III trial is studying radiation therapy with or without chemotherapy to see how well it works in treating patients with high-risk malignant salivary gland tumors that have been removed by surgery.
This is a Phase 1, open-label, uncontrolled, multicenter study in 3 distinct solid tumors. The study design is dose-escalation/de-escalation using a standard 3 + 3 design to evaluate the safety profile of ADXS-NEO, to select a recommended phase 2 dose (RP2D), and identify initial signs of clinical activity in each of the 3 tumor-specific cohorts.
MGCD516 is a Receptor Tyrosine Kinase (RTK) Inhibitor shown in preclinical models to inhibit a closely related spectrum of RTKs including MET, AXL, MER, and members of the VEGFR, PDGFR, DDR2, TRK and Eph families. In this study, MGCD516 is orally administered to patients with advanced solid tumor malignancies to evaluate its safety, pharmacokinetic, metabolism, pharmacodynamic and clinical activity profiles.
Patients anticipated to be enrolled in Phase 1b will be selected based upon having a tumor type, including but not limited to, Non-Small Cell Lung Cancer and Head and Neck Cancer positive for specific activating MET, NTRK2, NTRK3, or DDR2 mutations, MET or KIT/PDGFRA/KDR gene amplification, selected gene rearrangements involving the MET, RET, AXL, NTRK1, or NTRK3 gene loci, or having loss of function mutations in the CBL gene.
This study will look at patients with a complaint of Posterior nasal drip (PND) who undergo sinonasal surgery and will attempt to link posterior inferior turbinate hypertrophy (PITH) to PND. All patients will have a preoperative nasal endoscopy in clinic to assess for PITH. All patients will complete preoperative quality of life forms, previously validated Sino-nasal Outcome Test (SNOT 22) and Nasal Obstruction and Septoplasty Effectiveness (NOSE) forms. Patients will undergo a computed tomography (CT) scan as deemed appropriate by Dr. McCoul. Patients will then be electively enrolled for surgery. All the preceding steps will occur in the course of routine clinical care and are unchanged by study participation. While under general anesthesia, small biopsies of the posterior inferior turbinate, the anterior head of the inferior turbinate (at the incision site for routine submucosal resection of the inferior turbinate (SMRT), and the anterior nasal septum will be obtained and sent to pathology. The pathology department will then evaluate the biopsies for markers of inflammation.